Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024
Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.